{"id":55115,"date":"2026-01-22T10:53:30","date_gmt":"2026-01-22T02:53:30","guid":{"rendered":"https:\/\/flcube.com\/?p=55115"},"modified":"2026-01-22T10:53:32","modified_gmt":"2026-01-22T02:53:32","slug":"ascletis-selects-asc37-as-clinical-candidate-for-monthly-triple-agonist-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55115","title":{"rendered":"Ascletis Selects ASC37 as Clinical Candidate for Monthly Triple Agonist Therapy"},"content":{"rendered":"\n<p><strong>Ascletis Pharma Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1672:HKG\">HKG:\u202f1672<\/a>) announced it has selected <strong>ASC37<\/strong>, a <strong>next\u2011generation once\u2011monthly subcutaneous GLP\u20111R\/GIPR\/GCGR triple\u2011agonist peptide<\/strong>, as its clinical development candidate, positioning the company at the forefront of <strong>ultra\u2011long\u2011acting metabolic disease therapies<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Ascletis Pharma Inc. (HKEX:\u202f1672)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>ASC37 (GLP\u20111R\/GIPR\/GCGR triple\u2011agonist peptide)<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>Clinical candidate selection<\/td><\/tr><tr><td><strong>Dosing<\/strong><\/td><td>Once\u2011monthly subcutaneous injection (\u22641\u202fmL volume)<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>AISBDD platform + ULAP (ultra\u2011long\u2011acting platform)<\/td><\/tr><tr><td><strong>Differentiation<\/strong><\/td><td>Monthly vs. weekly competitors (e.g., retatrutide)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Metabolic diseases (obesity, diabetes, metabolic syndrome)<\/td><\/tr><tr><td><strong>Selection Date<\/strong><\/td><td>16\u202fJan\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Triple Agonist:<\/strong> Simultaneously activates <strong>GLP\u20111R (glucagon\u2011like peptide\u20111)<\/strong>, <strong>GIPR (gastric inhibitory polypeptide)<\/strong>, and <strong>GCGR (glucagon) receptors<\/strong> to achieve <strong>superior weight loss, glycemic control, and metabolic benefits<\/strong><\/li>\n\n\n\n<li><strong>AI\u2011Driven Discovery:<\/strong> Developed using Ascletis\u2019 proprietary <strong>AI\u2011assisted structure\u2011based drug discovery (AISBDD) platform<\/strong>, optimizing receptor binding affinity and selectivity<\/li>\n\n\n\n<li><strong>Ultra\u2011Long\u2011Acting Technology:<\/strong> <strong>ULAP technology<\/strong> enables <strong>monthly dosing<\/strong> with <strong>low injection volume (\u22641\u202fmL)<\/strong>, improving patient convenience vs. <strong>retatrutide<\/strong> (weekly) and <strong>semaglutide<\/strong> (weekly)<\/li>\n\n\n\n<li><strong>Market Position:<\/strong> <strong>First monthly triple agonist<\/strong> in China; potential <strong>best\u2011in\u2011class<\/strong> metabolic therapy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China Market<\/th><th>Global Market<\/th><\/tr><\/thead><tbody><tr><td><strong>Obesity\/Type\u202f2 Diabetes Patients (2026E)<\/strong><\/td><td>180\u202fmillion \/ 142\u202fmillion<\/td><td>650\u202fmillion \/ 537\u202fmillion<\/td><\/tr><tr><td><strong>GLP\u20111\/GIP\/GCGR Market (2030E)<\/strong><\/td><td>\u00a585\u202fbillion<\/td><td>$62\u202fbillion<\/td><\/tr><tr><td><strong>Triple Agonist Penetration<\/strong><\/td><td>0%<\/td><td>&lt;1%<\/td><\/tr><tr><td><strong>ASC37 Peak Market Share<\/strong><\/td><td>8%<\/td><td>2%<\/td><\/tr><tr><td><strong>Peak Revenue (2032E)<\/strong><\/td><td>\u00a56.8\u202fbillion<\/td><td>$1.24\u202fbillion<\/td><\/tr><tr><td><strong>Annual Cost (Est.)<\/strong><\/td><td>\u2013<\/td><td>$8,000\u201112,000<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Retatrutide<\/strong> (Eli Lilly) \u2013 <strong>Weekly triple agonist<\/strong>, Phase\u202fIII, <strong>not yet monthly<\/strong><\/li>\n\n\n\n<li><strong>Semaglutide<\/strong> (Novo Nordisk) \u2013 Weekly GLP\u20111, market leader<\/li>\n\n\n\n<li><strong>Tirzepatide<\/strong> (Eli Lilly) \u2013 Weekly GIP\/GLP\u20111 dual agonist<\/li>\n\n\n\n<li><strong>ASC37<\/strong> \u2013 <strong>First monthly triple agonist<\/strong>; <strong>differentiated convenience<\/strong> and <strong>AI\u2011optimized design<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> Ascletis\u2019 <strong>Hangzhou facility<\/strong> (capacity 5,000\u202fL) will produce ASC37 for Phase\u202fI; <strong>scale\u2011up to 20,000\u202fL<\/strong> planned for commercial launch<\/li>\n\n\n\n<li><strong>Clinical Development:<\/strong> <strong>Phase\u202fI initiation<\/strong> expected <strong>Q2\u202f2026<\/strong>; primary endpoint: <strong>safety, PK, PD markers<\/strong>; <strong>Phase\u202fII<\/strong> to evaluate <strong>weight loss and HbA1c reduction<\/strong><\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Eligible for <strong>fast\u2011track designation<\/strong> given <strong>monthly dosing innovation<\/strong> and <strong>obesity epidemic priority<\/strong><\/li>\n\n\n\n<li><strong>Commercial Strategy:<\/strong> Position as <strong>premium therapy<\/strong> for patients seeking <strong>convenience<\/strong>; <strong>NRDL negotiation<\/strong> planned for 2029<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial projections for ASC37. Actual results may differ due to competitive dynamics, clinical trial outcomes, and manufacturing challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026012000753_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026012000753_c.\"><\/object><a id=\"wp-block-file--media-8a54d042-2730-41bb-95a5-f9dcc5cf37a7\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026012000753_c.pdf\">2026012000753_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026012000753_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-8a54d042-2730-41bb-95a5-f9dcc5cf37a7\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ascletis Pharma Inc. (HKG:\u202f1672) announced it has selected ASC37, a next\u2011generation once\u2011monthly subcutaneous GLP\u20111R\/GIPR\/GCGR triple\u2011agonist&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,6],"tags":[189,980,4361],"class_list":["post-55115","post","type-post","status-publish","format-standard","hentry","category-company","category-rd","tag-ascletis-pharma","tag-hkg-1672","tag-hot-targets"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ascletis Selects ASC37 as Clinical Candidate for Monthly Triple Agonist Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ascletis Pharma Inc. (HKG:\u202f1672) announced it has selected ASC37, a next\u2011generation once\u2011monthly subcutaneous GLP\u20111R\/GIPR\/GCGR triple\u2011agonist peptide, as its clinical development candidate, positioning the company at the forefront of ultra\u2011long\u2011acting metabolic disease therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55115\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascletis Selects ASC37 as Clinical Candidate for Monthly Triple Agonist Therapy\" \/>\n<meta property=\"og:description\" content=\"Ascletis Pharma Inc. (HKG:\u202f1672) announced it has selected ASC37, a next\u2011generation once\u2011monthly subcutaneous GLP\u20111R\/GIPR\/GCGR triple\u2011agonist peptide, as its clinical development candidate, positioning the company at the forefront of ultra\u2011long\u2011acting metabolic disease therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55115\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-22T02:53:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T02:53:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55115#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55115\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ascletis Selects ASC37 as Clinical Candidate for Monthly Triple Agonist Therapy\",\"datePublished\":\"2026-01-22T02:53:30+00:00\",\"dateModified\":\"2026-01-22T02:53:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55115\"},\"wordCount\":392,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ascletis Pharma\",\"HKG: 1672\",\"Hot targets\"],\"articleSection\":[\"Company\",\"R&amp;D\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55115#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55115\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55115\",\"name\":\"Ascletis Selects ASC37 as Clinical Candidate for Monthly Triple Agonist Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-22T02:53:30+00:00\",\"dateModified\":\"2026-01-22T02:53:32+00:00\",\"description\":\"Ascletis Pharma Inc. (HKG:\u202f1672) announced it has selected ASC37, a next\u2011generation once\u2011monthly subcutaneous GLP\u20111R\\\/GIPR\\\/GCGR triple\u2011agonist peptide, as its clinical development candidate, positioning the company at the forefront of ultra\u2011long\u2011acting metabolic disease therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55115#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55115\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55115#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascletis Selects ASC37 as Clinical Candidate for Monthly Triple Agonist Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ascletis Selects ASC37 as Clinical Candidate for Monthly Triple Agonist Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Ascletis Pharma Inc. (HKG:\u202f1672) announced it has selected ASC37, a next\u2011generation once\u2011monthly subcutaneous GLP\u20111R\/GIPR\/GCGR triple\u2011agonist peptide, as its clinical development candidate, positioning the company at the forefront of ultra\u2011long\u2011acting metabolic disease therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55115","og_locale":"en_US","og_type":"article","og_title":"Ascletis Selects ASC37 as Clinical Candidate for Monthly Triple Agonist Therapy","og_description":"Ascletis Pharma Inc. (HKG:\u202f1672) announced it has selected ASC37, a next\u2011generation once\u2011monthly subcutaneous GLP\u20111R\/GIPR\/GCGR triple\u2011agonist peptide, as its clinical development candidate, positioning the company at the forefront of ultra\u2011long\u2011acting metabolic disease therapies.","og_url":"https:\/\/flcube.com\/?p=55115","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-22T02:53:30+00:00","article_modified_time":"2026-01-22T02:53:32+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55115#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55115"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ascletis Selects ASC37 as Clinical Candidate for Monthly Triple Agonist Therapy","datePublished":"2026-01-22T02:53:30+00:00","dateModified":"2026-01-22T02:53:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55115"},"wordCount":392,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ascletis Pharma","HKG: 1672","Hot targets"],"articleSection":["Company","R&amp;D"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55115#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55115","url":"https:\/\/flcube.com\/?p=55115","name":"Ascletis Selects ASC37 as Clinical Candidate for Monthly Triple Agonist Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-22T02:53:30+00:00","dateModified":"2026-01-22T02:53:32+00:00","description":"Ascletis Pharma Inc. (HKG:\u202f1672) announced it has selected ASC37, a next\u2011generation once\u2011monthly subcutaneous GLP\u20111R\/GIPR\/GCGR triple\u2011agonist peptide, as its clinical development candidate, positioning the company at the forefront of ultra\u2011long\u2011acting metabolic disease therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55115#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55115"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55115#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ascletis Selects ASC37 as Clinical Candidate for Monthly Triple Agonist Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55115"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55115\/revisions"}],"predecessor-version":[{"id":55117,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55115\/revisions\/55117"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}